Policy
Changes
Dashboard
Pricing
Sign in
Sign up free
Home
/
Changes
/
Independence Blue Cross
/
MA08.148d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™)
Back to dashboard
All Plans
Administrative
Medium impact
MA08.148d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™)
Independence Blue Cross
·
Pharmacy
Effective date
Not stated
We identified it
Jul 2, 2026
Days to comply
—
Summary
Failed to analyze policy change
Action Required
Action needed
Manual review required
Related policy hubs
Independence Blue Cross policies